Chinese state delegation prepares European visit:
This article was originally published in Clinica
Executive Summary
Representatives from China's State Drug Administration (SDA) are to visit EUCOMED, the European medical device association, on June 6, as part of a European tour to strengthen commercial and industrial ties. Led by Ren Dequan, deputy director general of the SDA, the delegation will include the director of the SDA's Department of Medical Devices (DMD), Hao Heping, the head of product registration, Chang Yongheng, and the directors of the SDA's five regional DMDs. The tour will take the delegation to France, Italy, Belgium and Germany. It will serve to highlight the huge potential of the Chinese healthcare industry and give European industry representatives an opportunity to discuss issues such as the new medical device regulations and healthcare reform (see Clinica No 843, p 7 and No 898, p 8).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.